Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Alteplase for acute ischemic stroke may be the first stroke intervention to have a significant public health impact. In February 1999, this therapy was conditionally licensed in Canada for acute ischemic stroke within three hours of symptom onset. However, considerable controversy exists regarding its safety, its wider applicability outside clinical trials, and its ultimate availability. In this article we review the thrombolytic literature, attempt to answer many of the concerns, provide new guidelines for its use, and cite the need for more information about whom we should and should not be treating with this therapy.

Type

Journal article

Journal

Can J Neurol Sci

Publication Date

11/2000

Volume

27

Pages

283 - 287

Keywords

Brain Ischemia, Canada, Cerebral Hemorrhage, Clinical Trials as Topic, Fibrinolytic Agents, Forecasting, Humans, Practice Guidelines as Topic, Stroke, Thrombolytic Therapy, Tissue Plasminogen Activator